Insider Selling: Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Sells 1,010 Shares of Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Iqbal Hussain sold 1,010 shares of the firm’s stock in a transaction on Friday, January 30th. The shares were sold at an average price of $25.01, for a total transaction of $25,260.10. Following the completion of the transaction, the insider directly owned 104,376 shares of the company’s stock, valued at approximately $2,610,443.76. This trade represents a 0.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Centessa Pharmaceuticals Stock Up 1.2%

CNTA traded up $0.29 on Tuesday, hitting $25.48. 1,005,598 shares of the company were exchanged, compared to its average volume of 1,624,695. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. The stock’s fifty day moving average is $25.47 and its 200-day moving average is $22.53. The company has a market cap of $3.43 billion, a PE ratio of -13.92 and a beta of 1.56. Centessa Pharmaceuticals PLC Sponsored ADR has a 12 month low of $9.60 and a 12 month high of $30.58.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). Equities research analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CNTA has been the subject of several research analyst reports. B. Riley lifted their target price on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, December 1st. Wall Street Zen raised Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, October 27th. TD Cowen reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 14th. Chardan Capital reissued a “buy” rating and issued a $30.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, January 2nd. Finally, Truist Financial raised their target price on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $38.50.

Institutional Trading of Centessa Pharmaceuticals

Large investors have recently bought and sold shares of the business. Avoro Capital Advisors LLC raised its stake in Centessa Pharmaceuticals by 116.2% during the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock worth $262,096,000 after acquiring an additional 5,808,080 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in shares of Centessa Pharmaceuticals by 20.8% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company’s stock valued at $110,415,000 after purchasing an additional 1,449,000 shares during the last quarter. Commodore Capital LP increased its position in Centessa Pharmaceuticals by 39.3% during the 2nd quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock worth $43,340,000 after purchasing an additional 930,711 shares in the last quarter. TCG Crossover Management LLC lifted its stake in Centessa Pharmaceuticals by 8.5% in the 3rd quarter. TCG Crossover Management LLC now owns 3,136,480 shares of the company’s stock valued at $76,060,000 after purchasing an additional 245,664 shares during the last quarter. Finally, Franklin Resources Inc. boosted its position in Centessa Pharmaceuticals by 0.6% in the third quarter. Franklin Resources Inc. now owns 2,558,414 shares of the company’s stock valued at $62,042,000 after buying an additional 14,875 shares in the last quarter. 82.01% of the stock is owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.